Anthropic is expanding the use of Claude across the life sciences industry through partnerships with six companies focused on drug discovery, biotechnology and clinical development. 🔹 Key Highlights 🧬 Six Partnerships: Anthropic is working with six life sciences companies to accelerate AI-powered drug development. 🧪 Generate Biomedicines: AI helped design a CAR T-cell component that was approximately 70% shorter and produced around 10× more cancer-targeting receptors in lab tests. 🧫 Divergence Labs: Claude generated approximately 35,000 antibody designs in one month. 📄 Enveda: AI reviewed 1,061 pages of manufacturing documents, reducing review time by 89%. 💊 Bristol Myers Squibb: BMS is using Claude for clinical trial planning and success estimates. 🚀 Claude for Science: Anthropic also launched Claude for Science and acquired Mithril Medicine. 💡 Why It Matters Anthropic’s expansion into life sciences demonstrates how AI models can move beyond general-purpose applications into highly specialized scientific workflows. Drug discovery, clinical planning and research documentation represent potentially large enterprise use cases for Claude. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified